Kairos Pharma (KAPA) plans to collaborate with PreCheck Health Services, a clinical laboratory specializing in genetic sequencing, to develop companion biomarkers for Kairos' ENV105 therapy targeting prostate and lung cancers.
The partnership aims to advance the "precision" of patient screening and therapy monitoring in phase 1 and 2 clinical trials of ENV105, advancing treatment by identifying patients who will benefit most, Kairos Pharma said Tuesday in a statement.
Kairos Pharma shares rose 16% in recent after-hours trading.
Price: 2.34, Change: +0.33, Percent Change: +16.42
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。